Quick Answer
Insight Molecular Diagnostics Inc. reported Diluted EPS of $1.65 per share (loss) for fiscal year 2025.
Insight Molecular Diagnostics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.65 | +64.6% |
| 2024 | -$4.66 | -24.3% |
| 2023 | -$3.75 | +71.7% |
| 2022 | -$13.25 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.34 | +65.3% | -13.3% |
| June 30, 2025 | -$0.30 | +16.7% | -15.4% |
| March 31, 2025 | -$0.26 | +77.0% | +73.5% |
| September 30, 2024 | -$0.98 | -21.0% | -172.2% |
| June 30, 2024 | -$0.36 | +66.4% | +68.1% |
| March 31, 2024 | -$1.13 | -382.5% | -39.5% |
| September 30, 2023 | -$0.81 | +50.0% | +24.3% |
| June 30, 2023 | -$1.07 | +27.7% | -367.5% |
- Insight Molecular Diagnostics Inc. showed an increase of +64.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Insight Molecular Diagnostics Inc.’s diluted eps has grown by 87.5% (from $13.25 per share (loss) to $1.65 per share (loss)).
- The most recent figure is from Insight Molecular Diagnostics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: